SB 030Alternative Names: SB-030; SBCV 030
Latest Information Update: 29 Oct 2015
At a glance
- Originator SYMIC Biomedical
- Class Proteoglycans; Vascular disorder therapies
- Mechanism of Action Inflammation mediator modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Peripheral arterial disorders